B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

TOP2A

MOLECULAR TARGET

DNA topoisomerase II alpha

UniProt: P11388NCBI Gene: 715314 compounds

TOP2A (DNA topoisomerase II alpha) is targeted by 14 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting TOP2A

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1myricetin-3-O-galactopyranoside [Supplementary Concept]1.614
2Daunorubicin1.614
3Genistein1.102
4Quercetin1.102
5Ethidium1.102
6Teniposide1.102
7Topotecan1.102
8Ciprofloxacin0.691
9fisetin0.691
10Aclarubicin0.691
11Dexrazoxane0.691
12Digitoxin0.691
13Epirubicin0.691
14Idarubicin0.691

About TOP2A as a Drug Target

TOP2A (DNA topoisomerase II alpha) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 14 compounds with documented TOP2A interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

TOP2A inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.